I agree with davidf104. Not sure there was anything to be "buying" (i.e. buy the rumor). What could that have been? Accelerated approval? Any oncology biotech investor understand that there was not an established "unmet medical need" for a TKI in RCC. There are currently four of them on the market. In addition, axitinib did not receive an accelerated approval either (standard 10 months). Comparisons to carfilzomib are poor - since there are no drugs approved for MM patients that fail both Revlmid and Velcade. Accelerated approval makes more sense in that market than for tivozanib in RCC.
Hence, the short attack makes perfect sense. Go to the nasdaq site and see how many shares keep accumulating in the short camp. Last time I checked it had doubled from mid-summer from ~2.5 million shares to well over 5 million shares. Classic short attack in my opinion. If we don't move up on the next positive day in Wall St, that will be confirmation of a rising short stake with the hedgies. #$%$ crazy.